Graticule Asia Macro Advisors LLC Argenx Se Transaction History

Graticule Asia Macro Advisors LLC

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$269.58 - $378.88 $3.93 Million - $5.53 Million	-14,585 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$254.45 - $351.06 $3.71 Million - $5.12 Million	14,585 New	14,585 $4.6 Million
Q2 2019 Aug 14, 2019	SELL	$115.0 - $141.58 $4.99 Million - $6.15 Million	-43,410 Closed	0 $0
Q1 2019 May 15, 2019	BUY	$98.85 - $134.59 $4.29 Million - $5.84 Million	43,410 New	43,410 $5.42 Million

400

30.9M

376K

489K

Ticker ARGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,323,800
Market Cap $34.9B
Description
argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...

Get notified when there are updates to the investment portfolio of Graticule Asia Macro Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Graticule Asia Macro Advisors LLC with notifications on news.